US278923A
(en)
*
|
|
1883-06-05 |
|
Newspapee weappee |
CA1288425C
(en)
|
1986-03-12 |
1991-09-03 |
Michael V.J. Ramsay |
Macrolide compounds
|
EP0512042B1
(en)
|
1990-01-24 |
1998-04-08 |
BUCKLEY, Douglas I. |
Glp-1 analogs useful for diabetes treatment
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
DK39892D0
(en)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
PEPTIDE
|
JPH08510205A
(en)
|
1993-03-29 |
1996-10-29 |
ユニバーシティ オブ シンシナティ |
YY peptide analogs and their uses
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
EP0803255A4
(en)
|
1994-06-03 |
1999-06-30 |
Tsumura & Co |
Medicinal composition
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5574010A
(en)
|
1994-11-14 |
1996-11-12 |
The Regents Of The University Of California |
Treatment of pancreatic tumors with peptide YY and analogs thereof
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
US5866536A
(en)
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
SE9600070D0
(en)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
CA2468374C
(en)
|
1996-08-30 |
2010-12-21 |
Novo-Nordisk A/S |
Glp-1 derivatives
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
EP1529534B1
(en)
|
1996-11-12 |
2007-07-11 |
Novo Nordisk A/S |
Use of GLP-1 peptides
|
CA2271788A1
(en)
|
1996-11-13 |
1998-05-22 |
University Of Cincinnati |
Analogs of peptide yy and uses thereof
|
US5773647A
(en)
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
EP0908515A3
(en)
|
1997-09-16 |
2000-04-26 |
Smithkline Beecham Plc |
Pancreatic polypeptide
|
EP1056774A1
(en)
|
1998-02-27 |
2000-12-06 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
EP1060191B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Derivatives of glp-1 analogs
|
WO1999043707A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
WO1999043341A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
|
AU3247799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
US6046167A
(en)
|
1998-03-25 |
2000-04-04 |
University Of Cincinnati |
Peptide YY analogs
|
CN1311773A
(en)
|
1998-06-08 |
2001-09-05 |
先灵公司 |
Neuropeptide Y5 receptor antagonists
|
SE9802080D0
(en)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and / or irritable bowel syndrome and new use of substances therein
|
JP2002523333A
(en)
|
1998-07-31 |
2002-07-30 |
ノボ ノルディスク アクティーゼルスカブ |
Use of GLP-1 and analogs to prevent type II diabetes
|
MY155270A
(en)
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
CZ295044B6
(en)
|
1998-12-07 |
2005-05-18 |
Societe De Conseils De Recherches Et D'application |
Analogues GLP-1, having aminoisobutyric acid in positions 8 and 35, their use and pharmaceutical composition in which the analogues are comprised
|
EP1149066B1
(en)
|
1999-02-05 |
2005-11-09 |
Emisphere Technologies, Inc. |
Method of preparing alkylated salicylamides
|
EP1154761B1
(en)
|
1999-02-22 |
2008-02-20 |
Merrion Research I Limited |
Solid oral dosage form containing an enhancer
|
WO2000048589A1
(en)
|
1999-02-22 |
2000-08-24 |
Emisphere Holdings, Inc. |
Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
CN1372570A
(en)
|
1999-04-30 |
2002-10-02 |
安米林药品公司 |
Modified exendin and exendin agonists
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
SI1180121T1
(en)
|
1999-05-17 |
2004-04-30 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
GB9923436D0
(en)
|
1999-10-04 |
1999-12-08 |
American Home Prod |
Pharmaceutical compositions
|
US6793934B1
(en)
|
1999-12-08 |
2004-09-21 |
Shire Laboratories, Inc. |
Solid oral dosage form
|
WO2001092206A1
(en)
|
2000-06-02 |
2001-12-06 |
Emisphere Technologies, Inc. |
Method of preparing salicylamides
|
US7049283B2
(en)
|
2000-12-06 |
2006-05-23 |
Novartis Ag |
Pharmaceutical compositions for the oral delivery of pharmacologically active agents
|
ES2311560T3
(en)
|
2000-12-07 |
2009-02-16 |
Eli Lilly And Company |
GLP-1 FUSION PROTEINS.
|
WO2002048192A2
(en)
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
JP2004515533A
(en)
|
2000-12-14 |
2004-05-27 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
Peptide YY and peptide YY agonist for treating metabolic disorders
|
US6589938B2
(en)
|
2001-06-29 |
2003-07-08 |
National University Of Singapore |
Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
|
US20030068356A1
(en)
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
AU2002317599B2
(en)
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
PL205971B1
(en)
|
2001-09-24 |
2010-06-30 |
Imp Innovations Ltd |
Modification of feeding behavior
|
WO2003045331A2
(en)
|
2001-11-29 |
2003-06-05 |
Emisphere Technologies, Inc. |
Formulations for oral administration of cromolyn sodium
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
NZ534234A
(en)
|
2002-02-01 |
2007-05-31 |
Pfizer Prod Inc |
Dry granulated formulations of non-dihydrate form of azithromycin
|
MXPA04008068A
(en)
|
2002-02-20 |
2004-11-26 |
Lilly Co Eli |
Method for administering glp-1 molecules.
|
WO2004005342A1
(en)
|
2002-07-04 |
2004-01-15 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
JP2004131398A
(en)
|
2002-10-08 |
2004-04-30 |
Taihei Chemical Industrial Co Ltd |
Lubricant for tablet
|
EP1583549A4
(en)
|
2003-01-17 |
2006-10-04 |
Sod Conseils Rech Applic |
Peptide yy analogs
|
WO2004067548A2
(en)
|
2003-01-31 |
2004-08-12 |
Theratechnologies Inc. |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
MXPA05009940A
(en)
|
2003-03-19 |
2005-12-05 |
Lilly Co Eli |
Polyethelene glycol link glp-1 compounds.
|
BRPI0411165A
(en)
|
2003-05-14 |
2006-07-11 |
Emisphere Tech Inc |
pharmaceutical composition, dosage unit form and methods for preparing its use
|
US7572581B2
(en)
|
2003-06-30 |
2009-08-11 |
Roche Molecular Systems, Inc. |
2′-terminator nucleotide-related methods and systems
|
DE602004023093D1
(en)
|
2003-07-11 |
2009-10-22 |
Novartis Ag |
N WITH A DISPENSER IN MICRONIZED FORM
|
JP2007501811A
(en)
|
2003-08-08 |
2007-02-01 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Use of galactose oxidase for selective chemical conjugation of a retarder molecule to a protein of therapeutic interest.
|
CN101380476A
(en)
|
2003-09-19 |
2009-03-11 |
诺沃挪第克公司 |
Albumin-binding derivatives of therapeutic peptides
|
TW200526254A
(en)
|
2003-09-19 |
2005-08-16 |
Novo Nordisk As |
Novel GLP-1 derivatives
|
TW200522976A
(en)
|
2003-09-19 |
2005-07-16 |
Novo Nordisk As |
Novel plasma protein affinity tags
|
RU2421238C2
(en)
|
2003-11-20 |
2011-06-20 |
Ново Нордиск А/С |
Peptide composition containing propylene glycol optimal for manufacturing and application in injection devices
|
ATE461217T1
(en)
|
2003-12-18 |
2010-04-15 |
Novo Nordisk As |
GLP-1 COMPOUNDS
|
CN101665538A
(en)
|
2003-12-18 |
2010-03-10 |
诺沃挪第克公司 |
Novel GLP-1 analogues linked to albumin-like agents
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
NZ548978A
(en)
|
2004-02-11 |
2009-10-30 |
Amylin Pharmaceuticals Inc |
Hybrid polypeptides with selectable properties
|
EP2335715A3
(en)
|
2004-02-11 |
2013-12-18 |
Amylin Pharmaceuticals, LLC |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
MXPA06010347A
(en)
|
2004-03-17 |
2007-06-19 |
7Tm Pharma As |
Y2 selective receptor agonists for therapeutic interventions.
|
AU2005224027B2
(en)
|
2004-03-17 |
2011-05-26 |
7Tm Pharma A/S |
Y2/Y4 selective receptor agonists for therapeutic interventions
|
CN100425282C
(en)
|
2004-03-17 |
2008-10-15 |
7Tm制药联合股份有限公司 |
Y2/Y4 selective receptor agonists for therapeutic interventions
|
PL2060266T3
(en)
|
2004-03-17 |
2012-01-31 |
7Tm Pharma As |
Y4 selective receptor agonist PP2-36 for therapeutic interventions
|
WO2005099672A1
(en)
|
2004-04-13 |
2005-10-27 |
Ranbaxy Laboratories Limited |
A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
|
AU2005240206B2
(en)
|
2004-05-06 |
2011-04-07 |
Emisphere Technologies, Inc. |
Solid dosage form of wetted heparin
|
CA2563681C
(en)
|
2004-05-06 |
2015-11-03 |
Emisphere Technologies, Inc. |
Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
|
CA2565188C
(en)
|
2004-05-14 |
2014-03-04 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
WO2005121090A1
(en)
|
2004-06-02 |
2005-12-22 |
Abbott Laboratories |
Substituted piperidines that have antiangiogenic activity
|
CN101010339B
(en)
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
BRPI0512988A
(en)
|
2004-07-08 |
2008-04-22 |
Novo Nordisk As |
method for increasing the plasma half-life of a molecule, compound, use thereof, and pharmaceutical composition
|
CN101443028A
(en)
|
2004-07-12 |
2009-05-27 |
爱密斯菲尔科技公司 |
Compositions for delivering peptide YY and PYY agonists
|
WO2006020207A2
(en)
|
2004-07-19 |
2006-02-23 |
University Of Cincinnati |
Compounds for control of appetite
|
US20060078623A1
(en)
*
|
2004-08-13 |
2006-04-13 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
WO2006049681A2
(en)
|
2004-08-30 |
2006-05-11 |
Bayer Pharmaceuticals Corporation |
Selective neuropeptide y2 receptor agonists
|
US7893017B2
(en)
|
2004-10-07 |
2011-02-22 |
Novo Nordisk A/S |
Protracted GLP-1 compounds
|
EP2330126B1
(en)
|
2004-10-07 |
2015-12-23 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
US7410949B2
(en)
|
2005-01-18 |
2008-08-12 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
|
US20080153779A1
(en)
|
2005-02-01 |
2008-06-26 |
Jun Liao |
Gastric Retention and Controlled Release Delivery System
|
EP2256130B1
(en)
|
2005-02-02 |
2013-09-25 |
Novo Nordisk A/S |
Novel insulin derivatives
|
EP1858546A4
(en)
|
2005-03-04 |
2009-03-04 |
Biorexis Pharmaceutical Corp |
Modified transferrin fusion proteins
|
GB0504857D0
(en)
|
2005-03-09 |
2005-04-13 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
RU2007134155A
(en)
|
2005-03-18 |
2009-04-27 |
Ново Нордиск А/С (DK) |
GLP-1 INCREASED HALF-TIME COMPOUNDS
|
JP2008533104A
(en)
|
2005-03-18 |
2008-08-21 |
ノボ ノルディスク アクティーゼルスカブ |
GLP-1 receptor dimer peptide agonist
|
CA2603105A1
(en)
|
2005-03-28 |
2006-10-05 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
CN101282991A
(en)
|
2005-05-26 |
2008-10-08 |
布里斯托尔-迈尔斯斯奎布公司 |
N-terminally modified GLP-1 receptor modulators
|
KR20080033392A
(en)
|
2005-07-11 |
2008-04-16 |
나스텍 파마수티컬 컴퍼니 인코포레이티드 |
Formulations for enhanced mucosal delivery of pyy
|
US8975227B2
(en)
|
2005-07-15 |
2015-03-10 |
Emisphere Technologies, Inc. |
Intraoral dosage forms of glucagon
|
US20090203581A1
(en)
|
2005-07-18 |
2009-08-13 |
Novo Nordisk A/S |
Novel Peptides for Use in the Treatment of Obesity
|
HUE045165T2
(en)
|
2005-08-19 |
2019-12-30 |
Amylin Pharmaceuticals Llc |
Exendin for treating diabetes and reducing body weight
|
US20070049557A1
(en)
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
AU2005337116A1
(en)
|
2005-09-21 |
2007-04-12 |
7Tm Pharma A/S |
Y4 selective receptor agonists for therapeutic interventions
|
EA200800875A1
(en)
|
2005-09-21 |
2008-08-29 |
7ТиЭм ФАРМА А/С |
RECEPTOR AGONISTS, SELECTIVE TO Y2 RECEPTOR, FOR TREATMENT EXPOSURE
|
WO2007061434A2
(en)
|
2005-11-10 |
2007-05-31 |
Nastech Pharmaceutical Company Inc. |
A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
|
WO2007061829A2
(en)
|
2005-11-17 |
2007-05-31 |
Novartis Ag |
Pharmaceutical composition
|
WO2007065808A2
(en)
|
2005-12-07 |
2007-06-14 |
F. Hoffmann-La Roche Ag |
Neuropeptide-2 receptor-agonists
|
JP2009520693A
(en)
|
2005-12-08 |
2009-05-28 |
エムディーアールエヌエー,インコーポレイテッド |
Mucosal delivery of stabilized exendin formulations
|
WO2007068718A1
(en)
|
2005-12-14 |
2007-06-21 |
Novo Nordisk A/S |
Polypeptide protracting tags
|
US20070197445A1
(en)
|
2006-01-18 |
2007-08-23 |
University Of Cincinnati |
Compounds for control of appetite
|
WO2007109354A2
(en)
|
2006-03-21 |
2007-09-27 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
US7704977B2
(en)
|
2006-04-07 |
2010-04-27 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
US8927015B2
(en)
|
2006-04-12 |
2015-01-06 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
KR101441444B1
(en)
|
2006-05-09 |
2014-09-18 |
노보 노르디스크 에이/에스 |
Insulin derivative
|
EP2040731A4
(en)
|
2006-06-09 |
2010-05-19 |
Merrion Res Iii Ltd |
Solid oral dosage form containing an enhancer
|
CA2656019C
(en)
|
2006-06-28 |
2016-09-13 |
Emisphere Technologies, Inc. |
Gallium nitrate formulations
|
GB0613196D0
(en)
|
2006-07-03 |
2006-08-09 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
ES2296529B1
(en)
|
2006-08-07 |
2009-04-01 |
Laboratorios Farmaceuticos Rovi, S.A. |
PHARMACEUTICAL COMPOSITION WITH ABSORPTION PROMOTERS.
|
EP2057189B1
(en)
|
2006-08-25 |
2013-03-06 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
EP2064175B1
(en)
|
2006-09-07 |
2014-08-06 |
F. Hoffmann-La Roche AG |
A process for the manufacture of snac (salcaprozate sodium)
|
TWI430806B
(en)
|
2006-09-13 |
2014-03-21 |
Smithkline Beecham Corp |
Methods for administering long-lasting hypoglycemic agents
|
PE20080845A1
(en)
|
2006-09-22 |
2008-08-13 |
Novartis Ag |
METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
WO2008070543A1
(en)
|
2006-12-01 |
2008-06-12 |
Emisphere Technologies Inc. |
Improved acyclovir formulations
|
US20090099074A1
(en)
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
WO2008087186A2
(en)
|
2007-01-18 |
2008-07-24 |
Novo Nordisk A/S |
Peptides for use in the treatment of obesity
|
EP2101822A2
(en)
|
2007-01-18 |
2009-09-23 |
Novo Nordisk A/S |
Use of peptides in combination with surgical intervention for the treatment of obesity
|
DE602008006700D1
(en)
|
2007-03-02 |
2011-06-16 |
Novartis Ag |
|
GB0708226D0
(en)
|
2007-04-27 |
2007-06-06 |
7Tm Pharma As |
Y-receptor agonists
|
JP2010530962A
(en)
|
2007-06-12 |
2010-09-16 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Methods for detecting proteins in plasma
|
BRPI0814629A2
(en)
|
2007-07-09 |
2015-01-27 |
Imp Innovations Ltd |
COMPOUNDS AND THEIR EFFECTS ON FOOD BEHAVIOR
|
WO2009032749A2
(en)
|
2007-08-29 |
2009-03-12 |
The Regents Of The University Of Californina |
Salicylanilide modified peptides for use as oral therapeutics
|
ES2672770T3
(en)
|
2007-09-05 |
2018-06-18 |
Novo Nordisk A/S |
Derivatives of glucagon-like peptide-1 and its pharmaceutical use
|
EP2190873B1
(en)
|
2007-09-05 |
2015-07-22 |
Novo Nordisk A/S |
Truncated glp-1 derivatives and their therapeutical use
|
EP2190460B1
(en)
|
2007-09-05 |
2014-12-17 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
JP2010539037A
(en)
|
2007-09-11 |
2010-12-16 |
モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト |
Use of peptides as therapeutic agents
|
US8598314B2
(en)
|
2007-09-27 |
2013-12-03 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase-inhibitor conjugates and methods of making and using same
|
WO2009050738A2
(en)
|
2007-10-16 |
2009-04-23 |
Biocon Limited |
An orally administerable solid pharmaceutical composition and a process thereof
|
JP5555634B2
(en)
|
2007-11-02 |
2014-07-23 |
エミスフェア テクノロジーズ インコーポレイティッド |
Method for treating vitamin B12 deficiency
|
US20090124639A1
(en)
|
2007-11-06 |
2009-05-14 |
Emisphere Technologies Inc. |
valacyclovir formulations
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
CN102027007A
(en)
|
2008-05-16 |
2011-04-20 |
诺沃-诺迪斯克有限公司 |
Long-acting Y2 and/or Y4 receptor agonists
|
US9186412B2
(en)
|
2008-08-18 |
2015-11-17 |
Entera Bio Ltd. |
Methods and compositions for oral administration of insulin
|
US8637647B2
(en)
|
2008-09-12 |
2014-01-28 |
Novo Nordisk A/S |
Method of acylating a peptide or protein
|
US8299023B2
(en)
|
2008-09-17 |
2012-10-30 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists
|
GB0817067D0
(en)
|
2008-09-18 |
2008-10-22 |
7Tm Pharma As |
Intestinal treatment
|
DK2386203T3
(en)
|
2008-10-15 |
2014-02-24 |
Bayer Cropscience Ag |
Use of dithiin-tetracarboximider for the control of phytopathogenic fungi
|
WO2010052144A2
(en)
|
2008-11-05 |
2010-05-14 |
F. Hoffmann-La Roche Ag |
Neuropeptide-2-receptor (y-2r) agonists and uses thereof
|
CN101463081B
(en)
|
2009-01-12 |
2012-07-04 |
华东师范大学 |
GLP-1 derivative
|
NZ594044A
(en)
|
2009-02-13 |
2014-08-29 |
Boehringer Ingelheim Int |
Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
CN102325545A
(en)
|
2009-02-20 |
2012-01-18 |
益普生制药股份有限公司 |
Peptide-cytotoxic conjugates with neuropeptide Y receptor binding compounds
|
AR077956A1
(en)
|
2009-09-14 |
2011-10-05 |
Bayer Cropscience Ag |
COMBINATIONS OF ACTIVE COMPOUNDS
|
CN102573888A
(en)
|
2009-09-18 |
2012-07-11 |
诺和诺德公司 |
Long-acting Y2 receptor agonists
|
EP2488195A2
(en)
|
2009-10-13 |
2012-08-22 |
F. Hoffmann-La Roche AG |
Neuropeptide-2 receptor (y-2r) agonists
|
WO2011058165A1
(en)
|
2009-11-13 |
2011-05-19 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
CA2784120A1
(en)
|
2009-12-16 |
2011-07-14 |
Nod Pharmaceuticals, Inc. |
Compositions and methods for oral drug delivery
|
WO2011073328A1
(en)
|
2009-12-16 |
2011-06-23 |
Novo Nordisk A/S |
Glp-1 receptor agonist compounds with a modified n-terminus
|
US20110182985A1
(en)
|
2010-01-28 |
2011-07-28 |
Coughlan David C |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
|
WO2011109787A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Methods of administering insulinotropic peptides
|
GB2478849A
(en)
|
2010-03-16 |
2011-09-21 |
Chiasma Inc |
Improved pharmecutical compositions and methods of delivery
|
WO2011131646A1
(en)
|
2010-04-20 |
2011-10-27 |
Novo Nordisk A/S |
Long-acting gastrin derivatives
|
US20130123460A1
(en)
|
2010-04-30 |
2013-05-16 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
|
WO2011138421A1
(en)
|
2010-05-05 |
2011-11-10 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
DE202010015867U1
(en)
|
2010-11-25 |
2011-05-05 |
Buchhalter, Thomas |
Electromechanical holder for holding navigation and communication devices in the vehicle
|
PL2651398T3
(en)
|
2010-12-16 |
2018-05-30 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
GB201101459D0
(en)
|
2011-01-27 |
2011-03-16 |
Imp Innovations Ltd |
Novel compounds and thier effects on fedding behaviour
|
CN103619175B
(en)
|
2011-04-12 |
2016-08-17 |
诺沃—诺迪斯克有限公司 |
Double acylated GLP-1 derivants
|
JP6006309B2
(en)
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals,Llc |
Engineered polypeptides with increased duration of action and reduced immunogenicity
|
DE102012102301B4
(en)
|
2012-03-19 |
2021-06-17 |
OSRAM Opto Semiconductors Gesellschaft mit beschränkter Haftung |
Optoelectronic semiconductor chip and headlight with such a semiconductor chip
|
HRP20231060T1
(en)
*
|
2012-03-22 |
2023-12-22 |
Novo Nordisk A/S |
Compositions of glp-1 peptides and preparation thereof
|
TR201903918T4
(en)
|
2012-03-22 |
2019-04-22 |
Novo Nordisk As |
Compositions containing a dispersing agent and their preparation.
|
JP6356660B2
(en)
*
|
2012-03-22 |
2018-07-11 |
ノヴォ ノルディスク アー/エス |
Compositions containing delivery agents and their preparation
|
US20150141336A1
(en)
|
2012-05-29 |
2015-05-21 |
Novo Nordisk A/S |
Pancreatic Peptide Compounds and Use
|
CN104487056A
(en)
*
|
2012-06-20 |
2015-04-01 |
诺和诺德A/S(股份有限公司) |
Tablet formulation comprising a peptide and a delivery agent
|
CA2877056A1
(en)
|
2012-07-01 |
2014-01-09 |
Novo Nordisk A/S |
Use of long-acting glp-1 peptides
|
WO2014178018A1
(en)
|
2013-05-02 |
2014-11-06 |
Glaxosmithkline Intellectual Property Development Limited |
Therapeutic peptides
|
PL2991671T3
(en)
*
|
2013-05-02 |
2019-01-31 |
Novo Nordisk As |
Oral dosing of glp-1 compounds
|
EP3068421B1
(en)
|
2013-11-15 |
2019-04-17 |
Novo Nordisk A/S |
Selective pyy compounds and uses thereof
|
CN105764919B
(en)
|
2013-11-15 |
2021-04-27 |
诺和诺德股份有限公司 |
hPYY (1-36) with a beta-homoarginine substitution at position 35
|
EP3129041B1
(en)
|
2014-04-07 |
2019-06-12 |
Novo Nordisk A/S |
Double-acylated glp-1 compounds
|
WO2016120380A1
(en)
*
|
2015-01-29 |
2016-08-04 |
Novo Nordisk A/S |
Pharmaceutical composition for oral glp-1 administration comprising a tablet core and immediate release coating
|
IL283258B2
(en)
|
2015-02-09 |
2023-11-01 |
Entera Bio Ltd |
Treatment of hypoparathyroidism
|
TWI694082B
(en)
|
2015-06-12 |
2020-05-21 |
丹麥商諾佛 儂迪克股份有限公司 |
Selective pyy compounds and uses thereof
|
EP3359181A1
(en)
|
2015-10-07 |
2018-08-15 |
Cyprumed GmbH |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
AR112015A1
(en)
|
2017-06-09 |
2019-09-11 |
Novo Nordisk As |
SOLID COMPOSITIONS FOR ORAL ADMINISTRATION
|
PE20211202A1
(en)
|
2017-08-24 |
2021-07-05 |
Novo Nordisk As |
COMPOSITIONS OF GLP-1 AND ITS USES
|
EP3746111B1
(en)
|
2018-02-02 |
2023-07-19 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
|
EP4009941A1
(en)
*
|
2019-08-07 |
2022-06-15 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|